Guggenheim Capital LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Guggenheim Capital LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 12,783 shares of the biopharmaceutical company’s stock after selling 2,465 shares during the quarter. Guggenheim Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $3,008,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $3,216,000. Mariner LLC grew its position in shares of Alnylam Pharmaceuticals by 16.6% in the 4th quarter. Mariner LLC now owns 13,666 shares of the biopharmaceutical company’s stock valued at $3,216,000 after buying an additional 1,947 shares during the last quarter. Townsquare Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $227,000. Sterling Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 601.0% during the 4th quarter. Sterling Capital Management LLC now owns 18,087 shares of the biopharmaceutical company’s stock worth $4,256,000 after acquiring an additional 15,507 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in Alnylam Pharmaceuticals by 2.7% in the fourth quarter. Treasurer of the State of North Carolina now owns 86,915 shares of the biopharmaceutical company’s stock valued at $20,452,000 after acquiring an additional 2,310 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ALNY shares. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Friday, March 21st. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $315.58.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ ALNY opened at $234.56 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. The firm has a 50-day moving average price of $249.14 and a 200 day moving average price of $256.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.